First patients receive IMA 901 in Phase III Trial for Renal Cell Carcinoma

Immatics Biotechnologies announced that the first patients have been vaccinated in the IMPRINT study, a Phase III trial with IMA 901, the company's lead cancer vaccine for the treatment of Renal Cell Carcinoma (RCC). The trial is designed to demonstrate the overall survival benefit of IMA 901 in combination with standard first-line therapy in RCC patients. IMPRINT is a global multicenter, randomized, controlled Phase III study in patients with metastatic and/or locally advanced RCC who are candidates for receiving standard first-line therapy with Sutent (sunitinib) from Pfizer. The trial will include approximately 330 patients across the US and Europe.